https://www.selleckchem.com/
Sugammadex is a novel agent for reversal of steroidal neuromuscular blocking agents (NMBAs) with potential advantages over acetylcholinesterase inhibitors. In preclinical trials, there have been rare instances of bradycardia with progression to cardiac arrest. To better define this issue, its incidence and mitigating factors, we prospectively evaluated the incidence of bradycardia after sugammadex administration in adults. Patients ≥ 18 years of age who received sugammadex were included in this prospective, open label trial. After administration, heart rate
Gefällt mir
Kommentar
Teilen
